AtriCure (ATRC)
(Delayed Data from NSDQ)
$34.41 USD
-0.69 (-1.97%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $34.39 -0.02 (-0.06%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ATRC 34.41 -0.69(-1.97%)
Will ATRC be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ATRC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ATRC
AtriCure (ATRC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
AtriCure (ATRC) Reports Q2 Loss, Tops Revenue Estimates
ATRC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Abbott (ABT) Q2 Earnings and Revenues Top Estimates
Has Amneal Pharmaceuticals (AMRX) Outpaced Other Medical Stocks This Year?
Are Medical Stocks Lagging Astellas Pharma (ALPMY) This Year?
Other News for ATRC
Bullish Two Hundred Day Moving Average Cross - ATRC
Decoding AtriCure Inc (ATRC): A Strategic SWOT Insight
AtriCure (ATRC) Price Target Raised Following Strong Quarterly Results
AtriCure (ATRC) Price Target Uplifted by Canaccord Analyst
AtriCure (ATRC): Needham Analyst Raises Price Target to $45 | ATRC Stock News